We classified GC patients into two molecular subtypes by EIRGs, and the prognosis of subtype A was worse compared with subtype B. Moreover, there were significant differences between the two subtypes in TME, with subtype A having a higher TME score than subtype B. EIRGs molecular subtypes are enriched in biological pathways such as EMT, IL6-JAK-STAT3 signaling, IL2-STAT5 signaling, and TGF-β signaling, and previous studies have shown that CAFs in GC cells enhance EMT by secreting IL-6 to activate the JAK2/STAT3 pathway in GC cells (Wu et al., 2017). The gene discussed is STAT3; the disease is gastric cancer.